Fig. 8

FasL neutralization increases the efficacy of immunotherapy. a, b Mice bearing Amela TiRP tumors received i.p. injections of soluble Fas-Fc and/or anti-Ly6G antibody, starting when tumor size reached 500 mm³, and repeated twice a week. ACT was applied 3 days after the first injection, and tumor volume was monitored (Mean ± s.e.m, n = 10 mice/group). c Mice treated as in (a, b) received anti-CTLA4 and anti-PD1 antibodies i.p. 1 day after the first injection of Fas-Fc/anti-Ly6G, and then twice a week for a total of four injections (Mean ± s.e.m; isotype: n = 10; CTLA4/PD1: n = 9; CTLA4/PD1/Ly6G/Fas-Fc: n = 10; this experiment was run together with the one described in (a, b) and the isotype control group is identical). d Mice bearing transplanted melanomas T429.11 received i.p. injections of anti-Ly6G and/or Fas-Fc starting when tumors became palpable, and repeated twice a week. 1 day later they received i.p. injections of anti-CTLA4 and anti-PD1, repeated twice a week for a total of four injections (Mean ± s.e.m; isotype: n = 7; CTLA4/PD1: n = 7; CTLA4/PD1/Fas-Fc: n = 10, CTLA4/PD1/Ly6G/Fas-Fc: n = 10; data pooled from two independent experiments). Depletion of Ly6G⁺ cells in tumors was checked after killing a–d. Two-way ANOVA a–d, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001